Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q3 2024 · 10-Q
Revenue—
Net Income-$5.10M-$5.10MN/M vs Q3 2023 EPS Diluted-$357.86-$357.86N/M vs Q3 2023 Operating Income-$5,213,000N/M Operating Cash Flowderived-$5,222,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 7, 2024 · 38 d after period end